Company: ARWR
Filing Date: 2025-01-29
Form Type: DEF 14A
Source: 0001628280-25-002848
Chunk: 30

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: DEF 14A
Chunk 30
---
 Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) (B-UNITED) A Phase 2b, Multi-centre, Randomized, Partially Placebo-controlled, Double-blind Study to Investigate the Safety and Efficacy of Sequential Therapy With Daplusiran/Tomligisiran Followed by Bepirovirsen in Participants With Chronic Hepatitis B Virus on Background Nucleos(t)Ide Analogue Therapy (B-United)

ClinicalTrials.gov Identifier: NCT05583344 Financial Results • Revenue — Generated revenue of $3.6 million, compared to revenues of $240.7 million in fiscal 2023 and $243.2 million in fiscal 2022; • Net Loss attributable to Arrowhead Pharmaceuticals, Inc. — Recorded net loss of $599.5 million, compared to net losses of $205.3 million in fiscal 2023 and $176.1 million in fiscal 2022; • Net Loss Per Share attributable to Arrowhead Pharmaceuticals, Inc. — Recorded net loss per share (diluted) of ($5.00), compared to net loss per share (diluted) of ($1.92) in fiscal 2023 and ($1.67) in fiscal 2022; • Cash at end of fiscal 2024 — Cash and investments of cash totaled $681.0 million at September 30, 2024; and • Total Stockholder Return — Achieved a three-year total stockholder return (“ TSR ”) at the 28th percentile of our peer group as measured in September 2024.

| 29 |

2025 PROXY STATEMENT The comparisons in the above graph are based on historical data and are not intended to forecast the possible future performance of our common stock. Executive Compensation Highlights Say-on-Pay Vote and Ongoing Response to Stockholder Feedback At our 2024 Annual Meeting of Stockholders, 94% of the stockholder votes cast on our non-binding, advisory proposal (the “ Say-on-Pay ” vote) on the executive compensation program were in favor of the program. Our Board of Directors was pleased with this result. We value the opinions of our stockholders and will continue to consider the outcome of future Say-on-Pay votes, as well as feedback received throughout the year, when making compensation decisions for our executive officers. The Compensation Committee is committed to